NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal CancerGlobeNewsWire • 01/15/21
Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The OncologistGlobeNewsWire • 11/30/20
NuCana Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/19/20
NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/17/20
NuCana Expands its Board of Directors with the Appointment of Bali MuralidharGlobeNewsWire • 10/13/20
NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary SharesGlobeNewsWire • 09/21/20
NuCana Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/19/20
NuCana Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 05/19/20
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 PandemicGlobeNewsWire • 05/18/20
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)GlobeNewsWire • 05/05/20
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian CancerGlobeNewsWire • 03/10/20
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract CancerGlobeNewsWire • 03/04/20